MedTrace Logo

JK-1201I in Triple Negative Breast Cancer Patients with Brain Metastases

NCT06586866 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2024-09-19

No results posted yet for this study

Summary

This study was designed to evaluate the safety, efficacy and pharmacokinetics of JK-1201I in triple negative breast cancer patients with brain metastases.

Conditions

  • Triple Negative Breast Cancer (TNBC)
  • Brain Metastasases

Interventions

DRUG

JK-1201I

JK-1201I will be administered as an IV infusion at dose of 125mg/m2 on Day 1 of each 14-day cycle.

Sponsors & Collaborators

  • JenKem Technology Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-26
Primary Completion
2026-05-26
Completion
2026-10-26

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06586866 on ClinicalTrials.gov